ANEB 1.96 Anebulo Pharmaceuticals, Inc.
| Range: | 1.72-3.3 | Vol Avg: | 7473 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | -1.02 | Cap: | 0.05B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri May 07 2021 | Empoloyees: | 2 | ||
| CUSIP: | 034569103 | CIK: | 0001815974 | ISIN: | US0345691036 | Country: | US |
| CEO: | Mr. Richard Anthony Cunningham | Website: | https://www.anebulo.com | ||||
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow